Efficacy of mirabegron, a β3-adrenergic agonist, switched from an anticholinergic agent for female patients aged over 70 years

In the present study, we investigated the efficacy of mirabegron, a β3-adrenergic agonist, in patients aged >70 years who did not respond to treatment with an anticholinergic agent. From February 2012 to May 2012, we examined 37 patients who did not respond to treatment with an anticholinergic agent...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 59(2013), 9 vom: 07. Sept., Seite 561-4
1. Verfasser: Nakanishi, Shinichi (VerfasserIn)
Format: Aufsatz
Sprache:Japanese
Veröffentlicht: 2013
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:English Abstract Journal Article Acetanilides Adrenergic beta-2 Receptor Agonists Cholinergic Antagonists Muscarinic Antagonists Thiazoles mirabegron MVR3JL3B2V
Beschreibung
Zusammenfassung:In the present study, we investigated the efficacy of mirabegron, a β3-adrenergic agonist, in patients aged >70 years who did not respond to treatment with an anticholinergic agent. From February 2012 to May 2012, we examined 37 patients who did not respond to treatment with an anticholinergic agent. We assessed the overactive bladder symptom score (OABSS), thirst, and constipation at baseline, as well as at 3 and 6 months from the start of drug administration. Theme an age of the female patients was 79.9±6.08 years. The OABSS indicated significant improvement in nocturia and urge incontinence at 3 and 6 months. Furthermore, mirabegron significantly relieved thirst (in 95.2% of cases) and constipation (in 87.5% of cases). Thus, mirabegron is considered useful for female patients aged >70 years who did not respond to treatment with an anticholinergic agent
Beschreibung:Date Completed 09.01.2014
Date Revised 11.10.2013
published: Print
Citation Status MEDLINE
ISSN:0018-1994